Copyright
©The Author(s) 2017.
World J Transplant. Dec 24, 2017; 7(6): 285-300
Published online Dec 24, 2017. doi: 10.5500/wjt.v7.i6.285
Published online Dec 24, 2017. doi: 10.5500/wjt.v7.i6.285
Disease | Presentation | Time of onset | Difference with native GN | Treatment | Prognosis |
MN | Proteinuria sometimes in nephrotic range | Late after transplant | Associated with trans-plant complications; IgG1 deposits instead of IgG4 | No specific treatment | Slowly progressive |
MPGN | Proteinuria, hematuria, NS, nephritic sediment | Months or years after transplant | Often associated with HCV, or with other diseases | Steroids + cytotoxic drugs if crescentic GN (?) | Slowly progressive; poor with many crescents. |
FSGS | Proteinuria, rarely in nephrotic range | Months or years after transplant | NS is rare; signs of rejection or CNI toxicity at biopsy | Removal of associated events | Usually poor, particularly in collapsing GN |
MCD | NS | Early after transplant | Mild mesangial sclerosis, hypercellularity | Steroids | Good |
- Citation: Abbas F, El Kossi M, Jin JK, Sharma A, Halawa A. De novo glomerular diseases after renal transplantation: How is it different from recurrent glomerular diseases? World J Transplant 2017; 7(6): 285-300
- URL: https://www.wjgnet.com/2220-3230/full/v7/i6/285.htm
- DOI: https://dx.doi.org/10.5500/wjt.v7.i6.285